Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Legend Biotech Corp ADR (NQ: LEGN ) 41.50 -0.95 (-2.24%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,098,380 Open 43.59 Bid (Size) 40.60 (1) Ask (Size) 42.60 (3) Prev. Close 42.45 Today's Range 41.10 - 43.59 52wk Range 38.60 - 77.32 Shares Outstanding 308,456,852 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst Today 12:15 EDT Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. Via Benzinga Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? June 09, 2024 Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. Via Benzinga Performance YTD -29.78% -29.78% 1 Month -8.65% -8.65% 3 Month -35.82% -35.82% 6 Month -33.12% -33.12% 1 Year -42.56% -42.56% More News Read More Unveiling 18 Analyst Insights On Legend Biotech June 04, 2024 Via Benzinga Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA June 03, 2024 From Legend Biotech Via Business Wire Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings) May 14, 2024 Via Benzinga Legend Biotech to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Legend Biotech Corporation Via Business Wire Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA May 23, 2024 From Legend Biotech Corporation Via Business Wire Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months May 13, 2024 Via Talk Markets LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024 May 13, 2024 Via InvestorPlace Analyst Ratings For Legend Biotech April 17, 2024 Via Benzinga Unveiling 9 Analyst Insights On Legend Biotech April 01, 2024 Via Benzinga Legend Biotech Reports First Quarter 2024 Results and Recent Highlights May 13, 2024 From Legend Biotech Corporation Via Business Wire CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma April 22, 2024 From Legend Biotech Corporation Via Business Wire FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies April 19, 2024 Via Benzinga Exposures Product Safety Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results April 11, 2024 From Legend Biotech Corporation Via Business Wire Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population April 08, 2024 Via Benzinga Exposures Product Safety Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma April 05, 2024 From Legend Biotech Corporation Via Business Wire GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy March 20, 2024 Via Benzinga Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report March 19, 2024 From Legend Biotech Corporation Via Business Wire FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer March 18, 2024 Via Benzinga Exposures Product Safety CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma March 15, 2024 From Legend Biotech Corporation Via Business Wire FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers March 13, 2024 Via Benzinga Exposures Product Safety Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session March 13, 2024 Via Benzinga Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights March 11, 2024 From Legend Biotech Corporation Via Business Wire Earnings Scheduled For March 11, 2024 March 11, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
